 |
UCB (EBR:UCB) Cimzia® Studies Show Significant Clinical Benefits For Mono- And Combination Therapy In Patients With Rheumatoid Arthritis
NOV 18, 2008 16:03 - Article Views: 420
UCB (EBR:UCB) * FAST 4WARD showed monotherapy Cimzia® 400 mg, dosed every four weeks, provided significant and effective clinical benefits compared to placebo
|
 |
|
Transparency Notification Of UCB (EBR:UCB) 's Reference Shareholders
NOV 1, 2008 07:21 - Article Views: 305
UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
|
|
|
UCB (EBR:UCB) Transparency Declaration By Capital Research And Management Company (CRMC)
NOV 1, 2008 06:35 - Article Views: 335
UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
|
|
|
UCB (EBR:UCB) Transparency Notification Of Wellington Management Company LLP
NOV 1, 2008 06:33 - Article Views: 366
UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
|
|
|
UCB (EBR:UCB) Fesoterodine Approved In The U.S.
NOV 1, 2008 05:33 - Article Views: 494
UCB (EBR:UCB) UCB entitled to receive milestone payment and royalties from Pfizer
|
|
|
UCB (EBR:UCB) On Track
OCT 31, 2008 17:03 - Article Views: 514
UCB (EBR:UCB) * UCB on track to achieve 2008 and 2009 financial outlook * Three new drug launches in nine months * Continued roll-out of strategy * Early research with two new external partnerships
|
|
|
UCB (EBR:UCB) New Cimzia® Study Shows Rapid Reduction Of Symptoms And Progression Of Rheumatoid Arthritis
OCT 31, 2008 11:36 - Article Views: 401
UCB (EBR:UCB) Patients treated with Cimzia®, together with methotrexate (MTX), experienced a rapid and clinically significant improvement in physical function, pain and fatigue as early as week one.
|
|
|
UCB (EBR:UCB) 's Vimpat® Approved By U.S. FDA As Adjunctive Therapy For Partial
Onset Seizures In Adults
OCT 29, 2008 17:03 - Article Views: 180
UCB (EBR:UCB) * New antiepileptic drug with a novel mechanism of action * Vimpat® helped people with epilepsy who still had uncontrolled partial onset seizures with current treatment * Vimpat® will be available in the U.S. as oral tablets and intravenous (IV) infusion * Vimpat® should be launched in the U.S. early 2009 by the well-established UCB epilepsy team
|
|
|
UCB (EBR:UCB) Withdraws EU Marketing Authorisation Application For Lacosamide
In Diabetic Neuropathic Pain
SEP 26, 2008 02:03 - Article Views: 164
UCB (EBR:UCB) Brussels, BELGIUM, September 25, 2008 at 06:00 pm CET - press release, regulated information: UCB announced today that it is withdrawing the European Marketing Authorisation Application with the European Medicines Agency (EMEA) for Vimpat® (lacosamide) in the treatment of diabetic neuropathic pain.
|
|
